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Standardization of mesenchymal stromal cell therapy
for perianal fistulizing Crohn’s disease
Ilse Molendijka, Andrea E. van der Meulen – de Jonga, Hein W. Verspageta, Roeland A. Veenendaala,
Daniel W. Hommesc, Bert A. Bonsingb and Koen C.M.J. Peetersb
Background Local administration of mesenchymal stromal cells (MSCs) into the fistula tract seems to improve patient outcome
in perianal fistulas due to Crohn’s disease (CD). In this paper we propose a standardized and validated protocol for the local
administration of MSCs for CD perianal fistulas to be able to reliably assess efficacy.
Materials and methods A working group consisting of gastroenterologists and surgeons with expertise in the treatment of
perianal CD developed a consensus perianal fistula treatment protocol for local MSC treatment of perianal fistulizing CD. The
treatment protocol was validated during a trial of allogeneic bone marrow-derived MSCs for the treatment of refractory perianal
Crohn’s fistulas.
Results Localization and classification of perianal fistulas with MRI and rectoscopy is of crucial importance prior to surgical
intervention with local therapy administration. Examination under anesthesia is necessary to incise and drain abscesses when
present. Optimization of medical treatment when active luminal CD is present, is the first step before embarking on surgery and
local therapy administration. In addition, strictures preventing the surgeon from adequately performing the surgical procedure
have to be endoscopically dilated. Curettage of the fistula tract has an important role as long-standing CD perianal fistulas close
poorly without removal of their epithelial lining. To diminish bacterial contamination of the fistula, the internal opening has to be
closed. The origin of the fistula is the internal opening, therefore, efficacy of MSCs is presumably the highest when they are
injected into the tissue around the internal opening.
Conclusion In this article, we propose a standardized method of local MSC administration for perianal fistulizing CD. The use of
this standardized and validated protocol for the administration of local treatment of CD perianal fistulas will allow reliable
comparison of the efficacy of local therapies in future. Eur J Gastroenterol Hepatol 30:1148–1154
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Despite all the recent advances in medical and surgical therapy
for Crohn’s disease (CD), durable remission rates for perianal
fistulas in CD still remain low [1]. The treatment outcome of
perianal fistulas is dependent on multiple factors. It is likely
that not only the activity of the underlying inflammatory
disease but also genetic and microbiological factors determine
the clinical course of CD fistulas and the success rates of
medical and surgical treatment. Antitumor necrosis factor
(TNF) agents such as infliximab, especially combined with
antibiotics, are effective in treating perianal fistulas [2,3].
However, more than one-third of the patients with an initially
healed perianal fistula after infliximab treatment had a recur-
rence of their fistula within 5 years [4]. Surgically, fistulotomy
is an effective treatment for simple superficial fistulas, with
success rates of 80–100% [5]. Unfortunately, most patients
with perianal fistulizing CD have complex fistulas, often with
multiple branches and involvement of the anal sphincters. A
temporary noncutting seton attempts to promote drainage and
fibrosis and aims to decrease inflammation, which is crucial
before embarking on fistula closure. However, fistula healing
rates after fibrin glue treatment (38%) or the insertion of an
anal fistula plug (55%) are disappointing [6,7]. A mucosal
advancement flap is successful in 64%, but incontinence
occurs in almost 10% of the treated patients [8].
Recently, the administration of local therapies for perianal
fistulas has emerged as an alternative approach. Various
studies have reported encouraging results of a local injection
of anti-TNF [9–13] into the fistula tract and local cellular
therapy with mesenchymal stromal cells (MSCs) [14–17].
Last year, the results of a large multicenter phase III trial on
allogeneic adipose-derived stem cells for the treatment of
refractory complex perianal fistulas in patients with CD were
published [18]. Fifty percent of the patients receiving MSCs
compared with 34% in the placebo group achieved remission
of their perianal fistulas. MSCs are multipotent cells capable
of modulating immune responses by interfering in the differ-
entiation of T cells [19] and maturation of antigen-presenting
cells [20]. In addition, MSCs are able to ‘sense’ inflammation
as they appear to be capable of migrating to the damaged
tissue to contribute toward the repair process [21–24].
However, the number ofMSCs that specifically migrate to the
site of inflammation is low after systemic injection and,
therefore, local injection might enhance their therapeutic
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efficacy [25–27]. Indeed, local injection of fibrin glue in
combination with MSCs resulted in higher fistula healing
rates compared with treatment with fibrin glue alone (71 vs.
16%) [14]. An even higher complete closure rate of 82% was
observed in a recently published phase II trial including 43
patients with perianal Crohn’s who received MSCs locally
proportioned to fistula length without additional fibrin glue
[17]. Further studies using a local injection of MSCs origi-
nating from both adipose tissue and bone marrow without
fibrin glue have also shown reductions in the number of
draining CD perianal fistulas [15,16]. Although this mode of
therapy administration seems to be effective, preoperative
workup and practice among surgeons in terms of injection
techniques is likely to differ considerably. To standardize local
therapy for perianal Crohn’s, we developed a new standar-
dized approach and validated this during a recent study of
MSC therapy for perianal fistulizing CD [28].
Patients and methods
Development of a standardized treatment protocol
A working group consisting of inflammatory bowel disease
(IBD)-specialized gastroenterologists and surgeons with
expertise on perianal CD from the Leiden University
Medical Center in the Netherlands was formed to develop
a standardized protocol for the local MSC treatment of
perianal fistulizing CD. The working group reached deci-
sions by consensus on the following four topics: (a) loca-
lization and classification of perianal fistulas, (b) surgical
intervention prior to therapy administration, (c) local MSC
administration, and (d) follow-up.
Validation of the standardized treatment protocol
Validation of the standardized treatment protocol was per-
formed during our recently published study on allogeneic
bone marrow-derived MSCs for the treatment of refractory
perianal Crohn’s fistulas [28]. Eligible patients had refractory
actively draining perianal fistulas with 1–2 internal openings
and 1–3 fistula tracts. Patients with rectovaginal fistulas or
complex perianal fistulas with more than two internal open-
ings were not included in this trial. In total, 21 (57.1% male)
patients with a mean age of 38.0 years were included. The
mean fistula duration was 5.5 years and most fistulas were
complex (65.2%) and trans-sphincteric (65.2%) [28].
The study was approved by the Medical Ethical
Committee of the Leiden University Medical Center
(LUMC) and the Central Committee on Research invol-
ving Human Subjects (The Hague, Netherlands) and all
patients gave written informed consent.
Results
Consensus of the standardized treatment protocol
Localization and classification of perianal fistulas
MRI: classification of perianal fistulas by determining the
location of the internal opening and the exact route of the
fistula with respect to both sphincters is of crucial impor-
tance before embarking on surgery. Examination under
anesthesia (EUA) is essential when an abscess is present to
be able to incise and drain the abscess (Fig. 1).
Rectoscopy: active proctitis complicates surgical pro-
cedures. It is therefore advisable to rule out the presence of
proctitis with a rectoscopy. If proctitis is present, it is
important to optimize medical treatment before adminis-
tering MSCs. Strictures that prevent the surgeon from
adequately performing the surgical intervention and ther-
apy administration as described below should be treated
first by (repeated) endoscopic dilatation. If severe strictures
persist, MSC treatment should not be performed.
Surgical intervention before therapy administration
Fistulas must be drained adequately for at least 2 weeks
before embarking on the administration of MSC to pre-
vent abscess formation after MSC treatment. If not drained
adequately, do not administer MSC therapy, but optimize
drainage with the use of setons.
It was agreed to be of utmost importance to prevent
adverse effects by minimalizing surgical trauma to the anal
sphincter. Excessive and long-lasting stretch of the anal
sphincter during surgery must be avoided to reduce the
risk of decreased continence. As long-standing CD peria-
nal fistulas are often epithelialized, these fistulas will not
close without curettage of the fistula tract. Closure of the
internal opening is paramount to prevent continuous
contamination of the fistula tract with feces.
Local administration of mesenchymal stromal cells
The goal of local treatment with MSCs is the reduction in
the number of actively draining fistulas caused by CD.
Therefore, it was decided that MSCs need to be injected at
the origin of the fistula where the inflammation resides,
specifically in the walls of the fistula around the closed
internal opening. Injection into the fistula lumen should be
avoided as this is a waste of the therapeutic agent as the
Fig. 1. Consensus of the standardized treatment protocol. EUA, examina-
tion under anesthesia.
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majority will just seep out of the fistula opening. The num-
ber of injection sites was kept to a minimum to ensure
administration of enough MSCs per injection site.
Follow-up
First 6 h after local administration of MSCs: patients
should be observed closely for the first 6 h after local
therapy administration by continuously monitoring the
temperature, blood pressure, and pulse to be able to
quickly intervene when infusion reactions occur. If no
adverse events are observed after 6 h, the patient can be
discharged the same day.
After local administration of MSCs: in the first 1–2
weeks after local MSC administration, patients can experi-
ence anal pain and discharge from the treated fistula(s).
However, patients should be instructed to contact their IBD-
specialized gastroenterologist and/or – surgeon when fever
or a fluctuating painful perianal swelling develops to exclude
a perianal abscess. Most perianal abscesses can be diagnosed
easily during a physical examination. However, when a
physical examination is not conclusive and an abscess can-
not be ruled out completely, ultrasound can be used as a
quick and easy diagnostic tool.
The efficacy of the local treatment, defined as an absence
of discharge from the fistula(s) by gentle finger compression,
is determined at physical examination. MRI is not useful in
the evaluation of fistula healing within the first year after
local therapy administration as radiological healing can lag
behind clinical healing by a median of 1 year [29].
Feasibility and outcomes of surgical intervention with
local mesenchymal stromal cell administration
We validated the standardized treatment protocol in our
recently published study [28].
Two trained surgeons performed the surgical procedures.
Allogeneic bone marrow-derived MSCs were cryopreserved
at passage 1 in the good manufacturing practice facility and
then, 2 weeks before the injection, the cryopreserved MSCs
were thawed and replated to ensure sufficient numbers of
MSCs at the time of surgical intervention. The MSCs were
spindle shaped, greater than 90% CD73+/CD90+/CD105+,
less than or equal to 1% CD45+ and less than or equal to
0.01% CD3+. The viability was measured and 3×107 viable
cells were immediately transferred in a cold environment
(4–8°C) to the operating room.
In our hands, 5 ml of 3×107 allogeneic bone marrow-
derived MSCs (passage 2 in 20 patients; passage 3 in one
patient) yielded a fistula healing rate of 85.7% compared
with 33.3% in the placebo group at 12 and 24 weeks after
local MSC administration. Surgery with a local injection of
MSCs was feasible as we could perform the standard
surgical procedure in all included patients. In addition, the
surgical procedures took only 20–40min/patient depend-
ing on the number and complexity of the perianal fistulas.
Surgical intervention was well tolerated by all patients.
There were no cases of wound infection or bleeding
reported. Moreover, local MSC administration did not
lead to treatment-related adverse events.
Standardized treatment protocol
Localization and classification of perianal fistulas
MRI and a rectoscopy were performed to describe the
localization and classification of the perianal fistula(s)
following the Parks and ‘simple/complex’ criteria (Fig. 2)
[5,30,31]. In Fig. 3, possible routes of perianal fistulas are
schematically shown:
(1) Locate the internal opening(s):
(a) Use the ‘anal clock’ when the patient is in the
lithotomy position to describe the location.
(b) Use the anorectal junction to indicate the level of
the internal opening: below, at or above.
(2) Determine the exact route of the fistula(s) with respect
to both sphincters: intersphincteric, trans-sphincteric,
suprasphincteric, or extrasphincteric.
(3) Locate the external opening(s): use the ‘anal clock’
when the patient is in the lithotomy position to
describe the location.
(4) Assess the presence of horseshoeing: intersphincteric,
infralevator, or supralevator.
(5) Assess the presence of a rectovaginal fistula.
(6) Assess the presence of perianal abscesses: superficial or
supralevator.
If present, perform an EUA with incision and drainage
of the abscess.
(7) Perform a rectoscopy to assess luminal activity of CD:
(a) If proctitis is present, optimize medical treatment
before local therapy administration.
(b) If a stricture that might hinder the surgeon to
perform the SOPs is present, endoscopic dilatation
of the stricture before local therapy administration
is recommended.
Surgical intervention before local mesenchymal stromal cell
administration
Perform the surgery and local MSC administration under
general or epidural anesthesia with the patient in the
lithotomy position.
(1) Inspect the perianal area for external openings. Use a
Hill–Ferguson retractor for optimal exposure. To
optimize visibility, especially of the anal canal, use a
headlamp.
(2) Explore the fistula tract(s) and identify the connection
between the external and internal opening(s) by
introducing a malleable probe through the external
opening(s).
(3) Remove seton(s) if in situ.
(4) Trim the mucosa around the internal opening(s).
(5) Remove the tissue surrounding the external opening(s).
(6) Thoroughly scrape the entire fistula tract(s) using a
curette.
(7) Close the internal opening(s) with an absorbable
polydioxanone (PDS) II 4/0 interrupted suture.
(8) Check with a malleable probe by inserting it through
the external opening(s) if the internal opening(s) is/are
completely closed to prevent fecal contamination of
the tract. If not, repeat step 7.
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Local mesenchymal stromal cell administration
Inject equal volumes of MSCs at four quadrants around
the closed opening. Inject the MSCs into the fistula wall.
(1) Resuspend MSCs before injection.
(2) Use a long fine needle (20 G) for the administration
of MSCs.
(3) Half of the MSC suspension must be injected into the
fistula wall at four quadrants around the closed
internal opening(s) by introducing the syringe through
the anus.
(4) The second half of the MSC suspension must be injected
into the fistula wall at four quadrants as close as
possible to the closed internal opening(s) by introducing
the syringe through the external opening(s) into the
fistula tract(s) as far as possible.
Follow-up
The patient needs to be monitored for adverse events
related to the surgery and/or local MSC administration.
(1) Observe the patient with monitoring of the vital signs
during the first 6 h after local MSC administration for
infusion reactions. The patient can be discharged if no
adverse events are observed after 6 h.
Fig. 2. Standardized treatment protocol. Timeline of procedures. (1) Localization and classification of perianal fistulas; (2) surgical intervention before MSC
administration; (3) local MSC administration. EUA, examination under anesthesia; MSC, mesenchymal stromal cell; PDS, polydioxanone suture.
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(2) Instruct patients to contact their IBD-specialized
gastroenterologist and/or – surgeon if they develop a
fever and/or a fluctuating painful perianal swelling.
(3) Use ultrasound when there is suspicion of a perianal
abscess. If present, EUA with incision and drainage of
the abscess with subsequent placement of a noncutting
seton to promote drainage and reduce inflammation of
the fistula is the first step before embarking on surgery.
Antibiotics such as ciprofloxacin or metronidazole are
recommended.
Discussion
In this paper, we propose a standardized protocol for the
local administration of MSCs for perianal fistulizing CD that
we have validated in a recently performed clinical trial on
allogeneic bone marrow-derived MSCs for the treatment of
refractory perianal Crohn’s fistulas [28]. Differences in sur-
gical practice are likely to have an impact on treatment
outcome. Therefore, standardization is crucial to assess the
efficacy of current and future local treatment strategies.
The ultimate treatment goal is to achieve complete clo-
sure of the perianal fistulas. Unfortunately, treatment of
perianal fistulizing CD remains challenging despite a range
of both medical and surgical options, and is often accom-
panied by multiple relapses [1]. Therapeutic efficacy might
be enhanced when drugs or MSCs are locally administered.
Promising results after the local administration of MSCs
have been published, with fistula healing rates of 69–82% in
uncontrolled trials [14–17] and 50–80% in recently per-
formed randomized double-blind placebo-controlled trials
[18,28]. In addition, local therapy with anti-TNF agents
might also result in fistula closure; however, to date, only
open-label studies with small sample sizes and no
randomized-controlled trials have been reported [9–13].
Fistula remission rates vary considerably after local admin-
istration of anti-TNF agents (36–88%) possibly as a result of
the additional fistulectomy performed in the trial with the
highest efficacy rate [11].
Although fistula healing rates after local therapy with
MSCs are encouraging, there are substantial differences in
the techniques of administration, making it difficult to
reliably assess the effect of local therapy. Therefore, we
sought to develop and test a standardized treatment pro-
tocol. Although we have only validated this protocol for
use with MSCs, it is possible that this protocol could also
be implemented for local therapy with anti-TNF agents.
Our rationale behind the location of injection is the same
for all CD perianal fistulas and is likely to hold true irre-
spective of the type of local treatment. The origin of the
fistula is the internal opening in all CD perianal fistulas.
Therefore, we believe that local treatment should be
administered around the closed internal opening. Closure
of the opening prevents bacterial contamination of the
fistula. Moreover, the treatment is presumably most effi-
cacious when it remains for as long as possible at the site of
injection. Therefore, administration of the drugs should be
into the tissue surrounding the fistula as a treatment agent
that is left in the lumen of the fistula will automatically be
discharged from the tract. In addition, in the majority of
the patients with long-standing perianal fistulas, epithe-
lialization of the fistula tract is present [32]. Therefore,
curettage of the entire fistula tract is recommended as the
presence of epithelium inside the tract prevents fistula
closure. The possibility of local treatment of other types
of CD-related fistulas such as rectovaginal and enter-
ocutaneous fistulas has hardly been explored. Only one
small trial of five patients with CD-related rectovaginal
fistulas who were treated with allogeneic adipose-derived
MSCs has been published. Complete healing of the fistulas
was observed in three of the five patients [33]. It is plau-
sible that our standardized protocol could also be used in
the treatment of other types of fistulas as the origin of the
fistula remains the internal opening in the intestine.
Our proposed protocol was validated in 21 patients. The
protocol was feasible in 100% of patients as we were able to
perform the standardized procedures in all included patients
without treatment-related side effects. Although the number
of viable MSCs in the syringes leaving the good manu-
facturing practice facility was 3×107, it is possible that the
actual number of injected MSCs is lower as MSCs may
adhere to the plastic syringe despite careful resuspension.
Fig. 3. Schematic routes of perianal fistulas. (a) Single internal opening and single external opening; (b) single internal opening and two external openings;
(c) single internal opening and three external openings; (d) single internal opening with one blind ending tract and one external opening; (e) single internal
opening with horseshoeing and two external openings; (f) two internal openings with horseshoeing and one external opening.
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In addition, when the syringe with MSC suspension was
introduced through the external opening, we could not
ensure that all MSCs were indeed injected around the
internal opening. It is likely that in patients with a longer or
tortuous fistula tract, we were not able to reach the internal
opening through this route. However, only half of the MSC
suspension was injected by introducing the syringe through
the external opening; the other half was always administered
into the wall around the closed internal opening by intro-
ducing the syringe through the anus.
In this article, we propose a standardized method of
local MSC administration for perianal fistulizing CD. The
use of this standardized and validated protocol for the
administration of local treatment of CD perianal fistulas
will enable a reliable comparison of the efficacy of local
therapies in future.
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